Navigation Links
Differing reactions to anti clotting drugs may be due to genetic variation.,,

People who take anti clotting drugs like warfarin may react differently to the drug because of their genetic makeup.//

A sizable population of the world takes anti clotting medications in the event of heart attacks, stroke or major surgery to check harmful clotting of blood. However the difference in the reactions to the drugs have foxed the physicians for long and made it difficult to standardize the proper dosage of the drug. A little change in dose often may result in more reactions to blood flow.

Researchers of University of Washington in Seattle had discovered the variations in a gene that alters the way people respond to blood clotting medications. The gene encodes the CYP2C9 enzyme that metabolizes the anti clot drug and thus accounts for almost 10% variations of the reactions to the drug warfarin.

When are patients are tested for variations in reactions to medications, the tests mostly concentrate on the sex, age, weight and medical history of the patients. It may take months of visits to the physicians to find out the right dose for the patient even then. Genetic variations are often not considered here. The new research will emphasize the study of people’s reaction to medications and their genetic coding, also called pharmacogenetics.

Reference: National Institutes of Health, news release, June 2005
'"/>




Page: 1

Related medicine news :

1. Differing Ideas on Management of Alzheimer’s diseas
2. ZYBAN, The smoking cessation drug marked for its adverse reactions
3. Lupin flour may cause peanut allergy like reactions
4. Arsenic poisoning reactions can be traced to genes
5. stents Result in allergic reactions
6. Aspirin surpasses Modern Anti-clotting Drugs
7. Enduring anti-clotting treatment avails heart patients
8. Treatment over a longer period for blood clotting
9. Gum disease may be caused by blood clotting gene
10. Anlene brand of milk products will carry warnings about blood-clotting risks
11. Bivalirudin, a new anti-clotting drug may be a safer option for treatment of acute coronary conditions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: